Crizotinib in ROS1-rearranged non-small-cell lung cancer
Crizotinib shrank tumours in almost three quarters of patients with ROS1-rearranged lung cancer and controlled the disease for a median of 19 months, establishing ROS1 as a targetable driver and leading to the first approval.
Overview
Expansion cohort of a phase 1 study treating 50 patients with advanced ROS1-rearranged non-small-cell lung cancer with crizotinib 250 mg twice daily.
Objective response was 72 percent with median duration of response 17.6 months and median progression-free survival 19.2 months; the safety profile matched that seen in ALK-positive disease.
- Objective response 72 percent.
- Median progression-free survival 19.2 months.
ROS1 testing became standard in lung adenocarcinoma; crizotinib was the first approved ROS1 inhibitor and remains an option, though entrectinib, repotrectinib and taletrectinib now offer brain penetration and resistance coverage.
- Single-arm study of 50 patients.
- Poor brain penetration and the G2032R resistance mutation limit crizotinib.
Similar pages
not linked directly; found by shared links- TrialA Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)
Shares Crizotinib, ROS1-positive non-small-cell lung cancer.
- TrialA Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
Shares Crizotinib, ROS1-positive non-small-cell lung cancer.
- Key paperTRIDENT-1: repotrectinib in ROS1 fusion-positive non-small-cell lung cancer
Shares ROS1-positive non-small-cell lung cancer, New England Journal of Medicine.
- TrialA Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Shares Crizotinib, ROS1-positive non-small-cell lung cancer.
- TargetROS1
Shares Crizotinib, ROS1-positive non-small-cell lung cancer.
- TermOncogene addiction
Shares Crizotinib, ROS1-positive non-small-cell lung cancer.